{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:22:42Z","timestamp":1776831762014,"version":"3.51.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10741-020-09926-y","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T06:02:42Z","timestamp":1580882562000},"page":"447-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib"],"prefix":"10.1007","volume":"25","author":[{"given":"Grazia","family":"Casavecchia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustachio","family":"Agricola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Capalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Zicchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"De Gennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Maria","family":"Righini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Monte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-7408","authenticated-orcid":false,"given":"Natale Daniele","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mercuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"9926_CR1","first-page":"751","volume":"10","author":"JV Melo","year":"1996","unstructured":"Melo JV (1996) The molecular biology of chronic myeloid leukaemia. Leukemia. 10:751\u2013756","journal-title":"Leukemia."},{"key":"9926_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E","volume":"75","author":"JE Cortes","year":"1995","unstructured":"Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM (1995) Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer. 75:464\u2013470","journal-title":"Cancer."},{"key":"9926_CR3","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109:2303\u20132309","journal-title":"Blood."},{"key":"9926_CR4","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 110:3540\u20133546","journal-title":"Blood."},{"key":"9926_CR5","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH et al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 118:4567\u20134576","journal-title":"Blood."},{"key":"9926_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"9926_CR7","unstructured":"ICLUSIG\u00ae (ponatinib) tablets for oral use (2013) [prescribing information] Cambridge: ARIAD Pharmaceuticals, Inc"},{"key":"9926_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V116.21.210.210","volume":"116","author":"J Cortes","year":"2010","unstructured":"Cortes J, Talpaz M, Bixby D, Deininger M, Shah N, Flinn IW, Mauro M, O'Hare T, Hu S, Kan R, Rivera VM, Clackson T, Haluska F, Kantarjian H (2010) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 116:210","journal-title":"Blood"},{"key":"9926_CR9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, M\u00fcller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796","journal-title":"N Engl J Med"},{"key":"9926_CR10","unstructured":"Ponatinib in participants with resistant chronic phase chronic myeloid leukemia (CML) to characterize the efficacy and safey of a range of doses (OPTIC) ClinicalTrials.gov Identifier: NCT02467270"},{"key":"9926_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908\u2013916","journal-title":"Nat Med"},{"key":"9926_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2005.11.014","volume":"243","author":"YH Park","year":"2006","unstructured":"Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, Yim SV, Chung JH (2006) BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243:16\u201322","journal-title":"Cancer Lett"},{"key":"9926_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0107-13a","volume":"13","author":"A Hatfield","year":"2007","unstructured":"Hatfield A, Owen S, Pilot PR (2007) In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d. Nat Med 13:13","journal-title":"Nat Med"},{"key":"9926_CR14","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Ja\u00efs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 125:2128\u20132137","journal-title":"Circulation."},{"key":"9926_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.24360","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Jean Khoury H, Kantarjian H, Br\u00fcmmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C (2016) Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol 91:606\u2013616","journal-title":"Am J Hematol"},{"key":"9926_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators et al (2016) Lancet Oncol 17:612\u2013621","journal-title":"Lancet Oncol"},{"key":"9926_CR17","doi-asserted-by":"crossref","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM (2016) Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol 4","DOI":"10.1001\/jamaoncol.2015.5932"},{"key":"9926_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/VHRM.S108874","volume":"13","author":"N Aghel","year":"2017","unstructured":"Aghel N, Delgado DH, Lipton JH (2017) Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag 13:293\u2013303","journal-title":"Vasc Health Risk Manag"},{"key":"9926_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","volume":"5","author":"MG Pouwer","year":"2018","unstructured":"Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG (2018) The BCR-ABL1 inhibitors Imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med 5:55","journal-title":"Front Cardiovasc Med"},{"key":"9926_CR20","doi-asserted-by":"crossref","unstructured":"Cortes J, Kim D-W, Pinilla-Ibarz J et al (2015) Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial. EHA Learning Center. Cortes J:100486","DOI":"10.1200\/jco.2015.33.15_suppl.e18052"},{"key":"9926_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG (2016) Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res 48:84\u201391","journal-title":"Leuk Res"},{"issue":"6","key":"9926_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","volume":"22","author":"V Mercurio","year":"2016","unstructured":"Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G, Tocchetti CG, Ghigo A, Ameri P (2016) Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail 22(6):449\u2013458","journal-title":"J Card Fail"},{"key":"9926_CR23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood.V128.22.1883.1883","volume":"128","author":"E Hadzijusufovic","year":"2016","unstructured":"Hadzijusufovic E, Kirchmair R, Theurl M, Gamperl S, Lener D, Gutmann C, Stanzl U, Kirsch A, Frank S, Valent P (2016) Ponatinib exerts multiple effects on vascular endothelial cells: possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with ponatinib. Blood 128:1883","journal-title":"Blood"},{"key":"9926_CR24","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu283","volume":"35","author":"S Windecker","year":"2014","unstructured":"Authors\/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, J\u00fcni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A et al (2014) Eur Heart J 35:2541\u20132619","journal-title":"Eur Heart J"},{"key":"9926_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","volume":"120","author":"MC M\u00fcller","year":"2017","unstructured":"M\u00fcller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G (2017) Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol 120:52\u201359","journal-title":"Crit Rev Oncol Hematol"},{"key":"9926_CR26","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"Hokusai-VTE Investigators, B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415","journal-title":"N Engl J Med"},{"key":"9926_CR27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36:2017\u20132023","journal-title":"J Clin Oncol"},{"key":"9926_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624","journal-title":"N Engl J Med"},{"key":"9926_CR29","doi-asserted-by":"crossref","unstructured":"Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap \u00c1F, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol","DOI":"10.1016\/S2352-3026(14)70018-3"},{"key":"9926_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11886-015-0570-3","volume":"17","author":"S Shah","year":"2015","unstructured":"Shah S, Nohria A (2015) Advanced heart failure due to cancer therapy. Curr Cardiol Rep 17:16","journal-title":"Curr Cardiol Rep"},{"key":"9926_CR31","first-page":"1111","volume":"6","author":"KE Price","year":"2013","unstructured":"Price KE, Saleem N, Lee G, Steinberg M (2013) Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther 6:1111\u20131118","journal-title":"Onco Targets Ther"},{"key":"9926_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","volume":"143","author":"DR Talbert","year":"2015","unstructured":"Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S (2015) A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci 143:147\u2013155","journal-title":"Toxicol Sci"},{"key":"9926_CR33","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"9926_CR34","doi-asserted-by":"crossref","unstructured":"Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Force T, Remick SC (2014) Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst 106","DOI":"10.1093\/jnci\/dju232"},{"key":"9926_CR35","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, JM DC, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063\u20131093","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"9926_CR36","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","volume":"20","author":"GT Armstrong","year":"2012","unstructured":"Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK et al (2012) Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 20:2876\u20132884","journal-title":"J Clin Oncol"},{"key":"9926_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","volume":"61","author":"P Thavendiranathan","year":"2013","unstructured":"Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH (2013) Reducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fractoion and volunmes: application to patients undergoing cancer chetherapy. J Am Coll Cardiol 61:77\u201384","journal-title":"J Am Coll Cardiol"},{"key":"9926_CR38","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ehjci\/jex033","volume":"18","author":"C Santoro","year":"2017","unstructured":"Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, de Simone G, Trimarco B, De Placido S, Galderisi M (2017) 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging 18:930\u2013936","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"9926_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","volume":"11","author":"JC Plana","year":"2018","unstructured":"Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P (2018) Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC Cardiovasc Imaging 11:1173\u20131186","journal-title":"JACC Cardiovasc Imaging"},{"key":"9926_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","volume":"111","author":"TG Neilan","year":"2013","unstructured":"Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M (2013) Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 111:717\u2013722","journal-title":"Am J Cardiol"},{"key":"9926_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11886-016-0768-z","volume":"18","author":"B Pitekova","year":"2016","unstructured":"Pitekova B, Ravi S, Shah SV, Mladosievicova B, Heitner S, Ferencik M (2016) The role of imaging with cardiac computed tomography in cardio-oncology patients. Curr Cardiol Rep 18:87","journal-title":"Curr Cardiol Rep"},{"key":"9926_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","volume":"41","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Carrier M, Garcia DA, Lee AY (2016) Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. J Thromb Thrombolysis 41:81\u201391","journal-title":"J Thromb Thrombolysis"},{"key":"9926_CR43","first-page":"167","volume":"9","author":"P Ameri","year":"2018","unstructured":"Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, Novo G, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, Zito C, Mercuro G, Pagliaro P, Tocchetti CG (2018) Antineoplastic drug-induced cardiotoxicity: a redox perspective. Front Physiol 9:167","journal-title":"Front Physiol"},{"key":"9926_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29:277\u2013314","journal-title":"J Am Soc Echocardiogr"},{"key":"9926_CR45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1183\/13993003.01110-2015","volume":"47","author":"F-M Quilot","year":"2016","unstructured":"Quilot F-M, Georges M, Favrolt N, Beltramo G, Foignot C, Grandvuillemin A, Montani D, Bonniaud P, Camus P (2016) Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 47:676\u2013679","journal-title":"Eur Respir J"},{"key":"9926_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clml.2016.03.004","volume":"16","author":"HJ Khoury","year":"2016","unstructured":"Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F (2016) Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 16:341\u2013349","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9926_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","volume":"23","author":"SM Bair","year":"2013","unstructured":"Bair SM, Choueiri TK, Moslehi J (2013) Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 23:104\u2013113","journal-title":"Trends Cardiovasc Med"},{"key":"9926_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2459\/JCM.0000000000000667","volume":"19","author":"C Cadeddu Dessalvi","year":"2018","unstructured":"Cadeddu Dessalvi C, Deidda M, Mele D, Bassareo PP, Esposito R, Santoro C, Lembo M, Galderisi M, Mercuro G (2018) Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. J Cardiovasc Med 19:315\u2013323","journal-title":"J Cardiovasc Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-09926-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:20:35Z","timestamp":1650414035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-09926-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["9926"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-09926-y","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"5 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}